No Data
We Think Haisco Pharmaceutical Group (SZSE:002653) Can Stay On Top Of Its Debt
GF SEC: VERTEX JPM meeting update, focusing on the progress in the fields of domestic enterprise pain and kidney disease.
The success of Suzetrigine offers hope for the development of the Nav1.8 target, and based on its inherent mechanism advantages, it is expected to bring a new, safer, and more effective therapy for pain patients.
Chinese Drug Regulator Accepts Haisco Pharma Unit's Application for Advanced Tumor Drug
Haisco Pharmaceutical Group (002653.SZ) distribution of profits for the first three quarters: 1.35 yuan per 10 shares.
Haisco Pharmaceutical Group (002653.SZ) released an announcement stating that the equity distribution plan for the first three quarters of 2024 is: fixed...
Haisco Pharmaceutical Group (002653.SZ): Received the IND application acceptance notice for Innovative Drugs HSK41959 tablets.
Gelonghui, on January 16th, reported that Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary Shanghai Haisco Shennuo Pharmaceutical Technology Co., Ltd. recently received the "Acceptance Notification" for HSK41959 tablets issued by the National Medical Products Administration. HSK41959 tablets are a self-developed oral, potent, and highly selective small molecule inhibitor intended for the treatment of advanced solid tumors. According to the National Medical Products Administration's announcement on the "Classification and Application Materials Requirements for Chemical Drug Registration" (No. 44 of 2020) regarding the classification of chemical drug registration, this product belongs to Chemical Drug Category 1. Preclinical research.
Haisco Pharmaceutical Group (002653.SZ) proposes a profit distribution plan for the first three quarters of 2024: a distribution of 1.35 yuan for every 10 shares.
On December 30, Gelonghui reported that Haisco Pharmaceutical Group (002653.SZ) announced the profit distribution plan for the first three quarters of 2024: it intends to distribute a cash dividend of 1.35 yuan (including tax) for every 10 shares based on the existing total share capital of 1,119,917,970 shares, totaling a cash dividend of 0.151 billion yuan.
What Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) 26% Share Price Gain Is Not Telling You
